Factors Associated with the Efficacy of Intravenous Chlorpromazine for Delirium in Patients with Terminal Cancer

Factors Associated with the Efficacy of Intravenous Chlorpromazine for Delirium in Patients with Terminal Cancer - the Efficacy of Intravenous Chlorpromazine for Delirium

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029833

Enrollment

Registered

2017-11-05

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study focused on 97 patients who received intravenous administration of chlorpromazine as a symptomatic treatment of non-reversible delirium

Exclusion criteria

Exclusion criteria: 15 patients met the exclusion criteria. The exclusion criteria included 1) the consent of intravenous administration of chlorpromazine was not obtained from their families (3 patients), 2) psychiatric disorder prohibiting communication before the onset of delirium (7 patients), 3) presence of brain tumor in the lower cortex that is contraindicated (5 patients).

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study was identification of factors that are associated with intravenous chlorpromazine efficacy based on the comparison between clinically relevant responders and non-responders.	—

Countries

Japan

Contacts

Public ContactHideaki Hasuo

Kansai Medical University Department of Psychosomatic Medicine

hasuohid@hirakata.kmu.ac.jp072-804-0101

Outcome results